Galidesivir is another C‐nucleoside analog that resembles adenosine. However, the base is not linked to a ribose, but to an aza‐sugar. Although it is recognized as adenosine by RdRP, its properties are different enough to cause a disruption in chain elongation. Galidesivir has been used in the treatment of Ebola and Marburg virus infections, and in vitro studies against SARS‐ and MERS‐CoVs have suggested efficacy against CoVs. 221  Therefore, it is a likely future anti SARS‐CoV‐2 agent, and currently being studied in clinical trials. 222 ,  223